Bioavailability of a Divalproex Extended-Release Formulation versus the Conventional Divalproex Formulation in Adult Patients Receiving Enzyme-Inducing Antiepileptic Drugs

Clinical Drug Investigation

Volumn 23, Issue 10, 2003, Pages 661-670

  Sommerville, Kenneth W ^a   Dutta, Sandeep ^a,e   Biton, Victor ^b   Zhang, Yiming ^a   Cloyd, James C ^c   Uthman, Basim ^d  

^a ABBOTT LABORATORIES   (United States)

^b Arkansas Epilepsy Program   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e Building AP 13A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ENZYME INDUCING AGENT; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TOPIRAMATE; VALPROATE SEMISODIUM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED DRUG RELEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MEGADOSE; DRUG TOLERABILITY; EPILEPSY; FEMALE; HUMAN; INJURY; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0142074294     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323100-00005     Document Type: Article

References (9)

1. DEPAKOTE® tablets, Abbott Laboratories. In: Physicians' Desk Reference. 56th ed. Montvale (NJ): Medical Economics Company Inc., 2002: 430-36
2. Porter RJ. Chapter 10: How to use antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. New York: Raven Press, 1995
3. Thomson AH, Brodie MJ. Pharmacokinetic optimisation of anticonvulsant therapy. Clin Pharmacokinet 1992; 23 (3): 216-30
4. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7
5. DEPAKOTE® ER tablets, Abbott Laboratories. In: Physicians' Desk Reference. 56th ed. Montvale (NJ): Medical Economics Company Inc., 2002: 436-40
6. Horne RL, Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. J Clin Psychopharmacol 2003; 23 (2): 176-81
7. Dutta S, Zhang Y, Selness DS, et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 2002; 49: 1-10
8. Scheyer RD. Valproic acid drug interactions. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2002: 801-2
9. Dutta S, Cloyd JC, Granneman GR, et al. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Res 2003; 53 (1-2): 29-38